antisense therapeutics ltd.[ASX:ANP / OTC:ATHJY]Antisense Therapeutics (ASX:ANP & OTC:ATHJY) is an Australian publicly traded biopharmaceutical drug discovery and development company focused on development and commercialisation of novel antisense therapeutics for a variety of drug candidates including Duchenne Muscular Dystrophy (DMD), Multiple Sclerosis and Acromegaly. The products are in-licensed from Ionis Pharmaceuticals Inc. (NASDAQ:IONS), world leaders in antisense drug development and commercialisation. The Company is undertaking a clinical trial of ATL1102 in patients with DMD. The Company recently reported positive clinical results following completion of dosing of all patients in the trial.
https://www.sachsforum.com/3nif-presenters.html
Ann: ANP to Present at Neuroscience Innovation Forum in the US, page-10
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
